

said heteromeric receptor, or said ligand, [an antibody light or heavy chain, an antibody light chain which is associated with a corresponding antibody heavy chain, and an antibody heavy chain which is associated with a corresponding antibody light chain,] wherein said ligand or fragment thereof retains ligand-receptor binding capability and said chain of said homomeric receptor or fragment thereof, and said chain of said heteromeric receptor or fragment thereof retain ligand-receptor binding capability either alone or in association with a homologous or heterologous chain of said receptor; and

(b) a subunit of a heterodimeric proteinaceous hormone or a fragment thereof which retains the ability of the subunit to form a heterodimer with other subunits thereof;

wherein sequences (a) and (b) are joined either directly or through a peptide linker, and in which the sequences (b) in each of said two coexpressed sequences aggregate with each other to dimerize and form a heterodimer [complex].

2(Twice-Amended). A hybrid protein in accordance with claim 1, wherein said sequence (a) is selected from the group consisting of TNF Binding Protein 1 (TBP1), TNF Binding Protein 2 (TBP2) or a fragment of said TBP1 or TBP2 still containing the ligand binding domain; the extracellular domain of the IFN α / β receptor or the IFN γ receptor; a gonadotropin receptor or extracellular fragments thereof; [antibody light chains or fragments thereof; optionally associated with the respective

RECEIVED
JUL 19 2000
TECH CENTER 1600/29